Innovations In Clinical Neuroscience

2015 Abstracts of Poster Presentations

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: http://innovationscns.epubxp.com/i/631092

Contents of this Issue

Navigation

Page 15 of 17

Innovations in CLINICAL NEUROSCIENCE [ V O L U M E 1 2 , N U M B E R 1 1 – 1 2 , N O V E M B E R – D E C E M B E R 2 0 1 5 , S U P P L E M E N T C ] 16 BY ARTICLE TITLE A dvantages of utilizing an SSRO management model to complement neurocognitive vendor or pharmaceutical sponsor data review ....13 Cognitive function in vortioxetine clinical trials in major depressive disorder: a meta-analysis........................................5 [The] complexion of risk and error in patient selection for CNS clinical trials: detailed findings from a 16,000-patient eligibility review database......................14 Effect of as-needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder ..4 Efficacy and safety of ITI-007 in clinical studies of schizophrenia..........................5 Enhanced protection against duplicate enrollment in clinical trials by collaboration between two independent research subject registries ................................................12 Examining placebo effects on MATRICS battery measures in schizophrenia cognition clinical trials.............................7 Examining the impact of ongoing assessment feedback on site rater performance: does our work matter?.....9 High-resolution actigraphy and advanced signal processing objectively quantifies nocturnal scratching events in patients with atopic dermatitis ..............................6 Identical scorings of the PANSS vary significantly between different study types ......................................................10 (The) impact of electronic administration of the ADAS-Cog on clinical trial data quality ....................................................12 Improving data quality through an integrated approach to eClinical data collection, rater training, and rater performance monitoring ......................10 Individual PANSS items and study population drive the PANSS/CGI relationship ............................................11 Is a computer-simulated rater good enough to administer the Hamilton depression rating scale in clinical trials?.........................................10 Key factors for proactive study start-up and site activation in neuroscience studies ...................................................15 [A] methodology for evaluating clinical trial sites and raters based on performance data ........................................................11 Motivating factors for patient participation and completion in psychiatric clinical trials .......................................................14 [A] novel clinical trial design to evaluate the safety and efficacy of TAK-375SL in the maintenance treatment of bipolar I disorder: preliminary results ...................4 Predicting placebo responders through frame of reference shifts .......................15 Probabilistic sleep models as improved EEG-based biomarkers for subjective sleep quality ......................................................6 [A] randomized, double-blind, placebo- controlled, four-period, cross-over study assessing the next-day residual effects of flibanserin on simulated driving performance in healthy premenopausal female volunteers ...................................4 Relationship between the Positive and Negative Syndrome Scale (PANSS) and a self-reported level of functioning, measured by the Specific Level of Functioning Assessment Scale (SLOF) among patients with schizophrenia...........................................8 [A] retrospective analysis of the effects of protocol design on completion rates in Phase I studies in subjects with stable schizophrenia or schizoaffective disorder .................................................13 Rosenberg Hassman Mood Scale: assessing understanding of impairment self-rating instructions ...........................8 [The] Symptom of Trauma scale (SOTS): a new tool for measuring symptom severity in PTSD ......................................9 Synthesis of carnitine analogues for inhibition of carnitine palmitoyltransferase ................................3 [The] tablet-based Brief Assessment of Cognition (BAC App) for schizophrenia ..........................................7 Trends in the qualification and parameters and demographics of participants completing Human Abuse Liability (HAL) trials .......................................................14 Understanding site and subject preferences in technologies used to increase the reliability of clinical assessments: a multi-national survey ....................................................13 Alphabetical Index

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - 2015 Abstracts of Poster Presentations